Monosol sues BioDelivery over pain treatment
17-01-2017
Teva sued over opioid overdose drug
25-10-2016
Pavel Kapysh / Shutterstock.com
A Delaware Federal Court has upheld some of the validity of challenged claims in two patents related to BioDelivery Sciences’ (BDSI) opioid medication Belbuca (buprenorphine), but invalidated others.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
BioDelivery Sciences, Belbuca, US District Court for the District of Delaware
